Germantown, MD – According to filings with the U.S. Securities and Exchange Commission, Deka Biosciences is raising $25,886,661.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, John Mumm played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Deka Biosciences
Deka Biosciences, Inc., is an early-stage biotechnology company focused on generating the next generation targeted cytokine therapies to treat cancer and inflammatory diseases. Deka is developing the dual cytokine, (DiakineTM) platform. Diakines are comprised of optimized, stimulatory, or suppressive disease specific IL-10 variants coupled to other stimulatory or suppressive cytokines via a T1/2 life extending tissue targeting, non-immunogenic scFv technology.

To learn more about Deka Biosciences, visit http://www.dekabiosciences.com/

Contact:
John Mumm, Chief Executive Officer
301-256-4776
https://www.linkedin.com/in/john-mumm-4442071/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved